FREMONT, Calif., Jan. 3, 2018 /PRNewswire/ -- Ardelyx, Inc.
(NASDAQ: ARDX) today announced that Mike
Raab, president and chief executive officer of Ardelyx, will
present a company overview at the J.P. Morgan 36th Annual
Healthcare Conference on Wednesday, Jan. 10,
2018 at 10 a.m. PT. The
conference is taking place Jan. 8-11,
2018 at the Westin St. Francis in San Francisco.
To access the live webcast of Ardelyx's presentation please
visit the Events & Presentations page within the Investor page
of the Ardelyx website at ir.ardelyx.com. Replays of the webcast
will be available on the Ardelyx website for 60 days following the
conference.
About Ardelyx, Inc.
Ardelyx is focused on enhancing
the way people with cardiorenal diseases are treated by developing
differentiated, minimally systemic medicines. Ardelyx's cardiorenal
pipeline includes the Phase 3 development of tenapanor for the
treatment of hyperphosphatemia in people with end-stage renal
disease who are on dialysis and RDX013, a potassium secretagogue
program for the potential treatment of hyperkalemia. In addition to
its cardiorenal pipeline, Ardelyx has completed Phase 3 development
of tenapanor for the treatment of people with irritable bowel
syndrome with constipation and anticipates submitting a New Drug
Application to the U.S. Food and Drug Administration for this
indication in the second half of 2018. To efficiently bring its
treatments to market, Ardelyx is pursing strategic collaborations
in the U.S. and beyond, with established agreements with Fosun
Pharma in China and Kyowa Hakko
Kirin in Japan. For more
information, please visit http://www.ardelyx.com/ and connect
with us on Twitter @Ardelyx.
View original content with
multimedia:http://www.prnewswire.com/news-releases/ardelyx-announces-presentation-at-jp-morgan-36th-annual-healthcare-conference-300576482.html
SOURCE Ardelyx